NCT07005882View on ClinicalTrials.gov

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2028

Conditions
Breast Cancer PatientsBreast Cancer Early Stage Breast Cancer (Stage 1-3)HR+/HER2- Breast CancerRadiation Therapy
Interventions
DRUG

Elacestrant

Preoperative treatment

RADIATION

PULSAR

Preoperative treatment

Trial Locations (1)

50134

AOU Careggi Radiation Oncology Unit, Florence

All Listed Sponsors
lead

Azienda Ospedaliero-Universitaria Careggi

OTHER